These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31767020)

  • 1. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma.
    Labadie BW; Liu P; Bao R; Crist M; Fernandes R; Ferreira L; Graupner S; Poklepovic AS; Duran I; Maleki Vareki S; Balar AV; Luke JJ
    J Transl Med; 2019 Nov; 17(1):386. PubMed ID: 31767020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
    Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
    Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
    Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
    Front Immunol; 2021; 12():734646. PubMed ID: 34795663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion.
    Fu Q; Xu L; Wang Y; Jiang Q; Liu Z; Zhang J; Zhou Q; Zeng H; Tong S; Wang T; Qi Y; Hu B; Fu H; Xie H; Zhou L; Chang Y; Zhu Y; Dai B; Zhang W; Xu J
    Eur Urol; 2019 May; 75(5):752-763. PubMed ID: 30293904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma.
    Tripathi A; Lin E; Xie W; Flaifel A; Steinharter JA; Stern Gatof EN; Bouchard G; Fleischer JH; Martinez-Chanza N; Gray C; Mantia C; Thompson L; Wei XX; Giannakis M; McGregor BA; Choueiri TK; Agarwal N; McDermott DF; Signoretti S; Harshman LC
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma.
    García M; Palma MB; Verine J; Miriuka S; Inda AM; Errecalde AL; Desgrandchamps F; Carosella ED; Tronik-Le Roux D
    BMC Cancer; 2020 Jul; 20(1):624. PubMed ID: 32620162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response.
    Hajiran A; Chakiryan N; Aydin AM; Zemp L; Nguyen J; Laborde JM; Chahoud J; Spiess PE; Zaman S; Falasiri S; Fournier M; Teer JK; Dhillon J; McCarthy S; Moran-Segura C; Katende EN; Sexton WJ; Koomen JM; Mulé J; Kim Y; Manley B
    Clin Exp Immunol; 2021 Apr; 204(1):96-106. PubMed ID: 33346915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
    de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
    Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
    Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
    Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
    Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
    Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma.
    Zhu ZP; Lin LR; Lv TD; Xu CR; Cai TY; Lin J
    Oncol Rep; 2020 Nov; 44(5):2056-2066. PubMed ID: 33000227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of a Novel Immune-Related lncRNA Pair Signature with Prognostic Significance for Kidney Clear Cell Renal Cell Carcinoma.
    Sun JX; Xia QD; Liu CQ; Xu JZ; Xun Y; Lu JL; Hu J; Wang SG
    Dis Markers; 2021; 2021():8800358. PubMed ID: 34512816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of epithelial-mesenchymal transition markers in clear cell renal cell carcinoma.
    Xu H; Xu WH; Ren F; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
    Aging (Albany NY); 2020 Jan; 12(1):866-883. PubMed ID: 31915310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low expression of ferritinophagy-related NCOA4 gene in relation to unfavorable outcome and defective immune cells infiltration in clear cell renal carcinoma.
    Mou Y; Wu J; Zhang Y; Abdihamid O; Duan C; Li B
    BMC Cancer; 2021 Jan; 21(1):18. PubMed ID: 33402128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma (ccRCC) by Transcriptomics.
    Zhang S; Xu X; Wang Y; Zhu Y; Wang J; Wang H; Guo J
    Ann Clin Lab Sci; 2021 Sep; 51(5):597-608. PubMed ID: 34686501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of transforming growth factor beta induced (TGFBI) as an immune-related prognostic factor in clear cell renal cell carcinoma (ccRCC).
    Du GW; Yan X; Chen Z; Zhang RJ; Tuoheti K; Bai XJ; Wu HH; Liu TZ
    Aging (Albany NY); 2020 May; 12(9):8484-8505. PubMed ID: 32406866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
    Beuselinck B; Verbiest A; Couchy G; Job S; de Reynies A; Meiller C; Albersen M; Verkarre V; Lerut E; Méjean A; Patard JJ; Laguerre B; Rioux-Leclercq N; Schöffski P; Oudard S; Zucman-Rossi J
    Acta Oncol; 2018 Apr; 57(4):498-508. PubMed ID: 29095068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A four-gene signature predicts survival in clear-cell renal-cell carcinoma.
    Dai J; Lu Y; Wang J; Yang L; Han Y; Wang Y; Yan D; Ruan Q; Wang S
    Oncotarget; 2016 Dec; 7(50):82712-82726. PubMed ID: 27779101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.